Cullinan Oncology, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 62 full-time employees. The company went IPO on 2021-01-08. The firm is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081 in a Phase I/IIa, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.

CGEM Profile, Market Tickers and Other

CGEM profile